A study published in Nature describes an experimental therapy using bespoke immune cells to combat cirrhosis. Researchers engineered patient-derived cells to target scarring in the liver, achieving stabilization of the disease in an early-stage trial.
Cirrhosis, a condition marked by irreversible liver scarring, affects millions worldwide and often leads to organ failure. Current treatments focus on managing symptoms, with transplantation as the only curative option.
The therapy, tested in a small group of patients, showed sustained reduction in fibrosis markers over six months. No severe adverse events were reported, though long-term safety data remain limited.
The approach offers a potential alternative to transplant, reducing strain on donor organ shortages. Larger, randomized trials will be needed to confirm efficacy and durability.
Experts caution that the complexity and cost of manufacturing individualized cells could limit scalability.